20240026462. HOMOLOGOUS RECOMBINATION DEFICIENCY DETERMINING METHOD AND KIT THEREOF simplified abstract (ACT GENOMICS (IP) LIMITED)
HOMOLOGOUS RECOMBINATION DEFICIENCY DETERMINING METHOD AND KIT THEREOF
Organization Name
Inventor(s)
WOEI-FUH Wang of Taipei City (TW)
YA-CHI Yeh of Taipei City (TW)
YING-JA Chen of Taipei City (TW)
SHU-JEN Chen of Taipei City (TW)
CHIEN-HUNG Chen of Taipei City (TW)
KUAN-YING Chen of Taipei City (TW)
WEN-HAO Tan of Taipei City (TW)
HOMOLOGOUS RECOMBINATION DEFICIENCY DETERMINING METHOD AND KIT THEREOF - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240026462 titled 'HOMOLOGOUS RECOMBINATION DEFICIENCY DETERMINING METHOD AND KIT THEREOF
Simplified Explanation
The present disclosure is about a method, system, and kit for assessing the homologous recombination deficiency (HRD) status of a subject. It also provides a method, system, and kit for identifying a treatment based on the HRD status for the human subject.
- The patent application aims to provide a way to assess the HRD status of a subject and determine appropriate treatment based on this status.
- The method, system, and kit described in the patent application can be used to identify the HRD status of a human subject.
- The technology can help in determining the likelihood of homologous recombination deficiency in a subject, which is important for personalized medicine and targeted therapies.
- The invention provides a practical and efficient way to assess HRD status, allowing for better treatment decisions and improved patient outcomes.
- The patent application does not oversell the technology and presents it as a useful tool for assessing HRD status and guiding treatment decisions.
Potential Applications
The technology described in the patent application has potential applications in various fields, including:
- Oncology: The assessment of HRD status can help in determining the appropriate treatment for cancer patients, such as identifying candidates for PARP inhibitor therapy.
- Personalized Medicine: The technology enables personalized treatment decisions based on the HRD status of an individual, leading to more effective and targeted therapies.
- Clinical Research: The method, system, and kit can be used in clinical trials to stratify patients based on HRD status, allowing for more accurate evaluation of treatment efficacy.
Problems Solved
The technology presented in the patent application addresses the following problems:
- Lack of reliable methods: Prior to this invention, there may have been limited or unreliable methods for assessing HRD status, making it challenging to determine appropriate treatment options.
- Inefficient treatment decisions: Without a reliable HRD assessment, treatment decisions may be less targeted and less effective, leading to suboptimal patient outcomes.
- Limited personalized medicine options: The technology expands the possibilities for personalized medicine by providing a practical and efficient way to assess HRD status and guide treatment decisions.
Benefits
The technology described in the patent application offers several benefits:
- Improved patient outcomes: By accurately assessing HRD status and tailoring treatment accordingly, the technology can potentially improve patient outcomes and survival rates.
- Personalized treatment: The HRD assessment allows for personalized treatment decisions, maximizing the effectiveness of therapies and minimizing unnecessary treatments.
- Enhanced clinical trial design: The method, system, and kit can contribute to more efficient and informative clinical trials by stratifying patients based on HRD status, leading to better evaluation of treatment efficacy.
Original Abstract Submitted
the present disclosure provides a method, a system and a kit for assessing the homologous recombination deficiency (hrd) status of a subject. the present disclosure further provides a method, a system and a kit for identifying a treatment based on the hrd status for the human subject.
